Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNUWK2)

Drug Name

4-(3,4,5-Trimethoxyphenethyl)aniline Drug Info

Synonyms

CHEMBL86928; 4-(3,4,5-Trimethoxyphenethyl)aniline; 110997-90-5; Benzenamine, 4-[2-(3,4,5-trimethoxyphenyl)ethyl]-; 4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamine; 4-[2-(3,4,5-Trimethoxyphenyl)Ethyl]Aniline; NSC631359; ACMC-20mdvn; AC1L7PCU; AC1Q56FF; SCHEMBL6483085; CTK0G1952; DTXSID30327095; BPIQFCQFIYIISU-UHFFFAOYSA-N; ZINC1622338; BDBM50322061; 4'-Amino-3,4,5-trimethoxybibenzyl; AKOS030581735; NSC-631359; NCI60_010236; 4-[2-(3,5-Trimethoxyphenyl)Ethyl]Aniline; 4-[2-(3,4,5-trimethoxy-phenyl)ethyl]-phenylamine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 364705
CAS Number: CAS 110997-90-5
TTD Drug ID: DMNUWK2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[2]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[3]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[3]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[4]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[5]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[6]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[7]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[8]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[9]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66.
2	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
3	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
4	Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
5	Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
6	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
7	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
8	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
9	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)